Systemic Inflammation during and after Bronchiectasis Exacerbations: Impact of <i>Pseudomonas aeruginosa</i>
Bronchiectasis is a chronic structural disease associated with exacerbations that provoke systemic inflammation. We aimed to evaluate the systemic acute proinflammatory cytokine and its biomarker profiles during and after exacerbations and its relationship with the severity of episode, microbiologic...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2020-08-01
|
| Series: | Journal of Clinical Medicine |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2077-0383/9/8/2631 |
| _version_ | 1797558360500862976 |
|---|---|
| author | Rosario Menéndez Raúl Méndez Isabel Amara-Elori Soledad Reyes Beatriz Montull Laura Feced Ricardo Alonso Rosanel Amaro Victoria Alcaraz Laia Fernandez-Barat Antoni Torres |
| author_facet | Rosario Menéndez Raúl Méndez Isabel Amara-Elori Soledad Reyes Beatriz Montull Laura Feced Ricardo Alonso Rosanel Amaro Victoria Alcaraz Laia Fernandez-Barat Antoni Torres |
| author_sort | Rosario Menéndez |
| collection | DOAJ |
| description | Bronchiectasis is a chronic structural disease associated with exacerbations that provoke systemic inflammation. We aimed to evaluate the systemic acute proinflammatory cytokine and its biomarker profiles during and after exacerbations and its relationship with the severity of episode, microbiological findings, and the bronchiectasis severity index. This prospective observational study compared exacerbation and stable groups. Cytokine (interleukins (IL)-17a, IL-1β, IL-6, IL 8; tumor necrosis factor-alpha (α)) and high-sensitivity C-reactive protein (hsCRP) levels were determined by multiplex analysis on days 1, 5, 30, and 60 in the exacerbation group and on day 1 in the stable group. We recruited 165 patients with exacerbations, of which 93 were severe (hospitalized). Proinflammatory systemic IL-17a, IL-1β, IL-8, and tumor necrosis factor-α levels increased similarly on days 1 and 5 in severe and non-severe episodes, but on day 30, IL-17a, IL-8, and IL-6 levels were only increased for severe exacerbations. The highest IL-17a level occurred in patients with chronic plus the acute isolation of <i>Pseudomonas aeruginosa</i>. At 30 days, severe exacerbations were independently associated with higher levels of IL-17 (Odds ratio (OR) 4.58), IL-6 (OR 4.89), IL-8 (OR 3.08), and hsCRP (OR 6.7), adjusted for age, the bronchiectasis severity index, and treatment duration. Exacerbations in patients with chronic <i>P. aeruginosa</i> infection were associated with an increase in IL-17 and IL-6 at 30 days (ORs 7.47 and 3.44, respectively). Severe exacerbations elicit a higher systemic proinflammatory response that is sustained to day 30. Patients with chronic <i>P. aeruginosa</i> infection had impaired IL-17a reduction. IL-17a could be a useful target for measuring systemic inflammation. |
| first_indexed | 2024-03-10T17:29:07Z |
| format | Article |
| id | doaj.art-2360c315fe9a420f9da569498b527d7c |
| institution | Directory Open Access Journal |
| issn | 2077-0383 |
| language | English |
| last_indexed | 2024-03-10T17:29:07Z |
| publishDate | 2020-08-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Journal of Clinical Medicine |
| spelling | doaj.art-2360c315fe9a420f9da569498b527d7c2023-11-20T10:03:16ZengMDPI AGJournal of Clinical Medicine2077-03832020-08-0198263110.3390/jcm9082631Systemic Inflammation during and after Bronchiectasis Exacerbations: Impact of <i>Pseudomonas aeruginosa</i>Rosario Menéndez0Raúl Méndez1Isabel Amara-Elori2Soledad Reyes3Beatriz Montull4Laura Feced5Ricardo Alonso6Rosanel Amaro7Victoria Alcaraz8Laia Fernandez-Barat9Antoni Torres10Pulmonary Medicine Department, Hospital Universitario y Politécnico La Fe, 46023 Valencia, SpainPulmonary Medicine Department, Hospital Universitario y Politécnico La Fe, 46023 Valencia, SpainPulmonary Medicine Department, Hospital Universitario y Politécnico La Fe, 46023 Valencia, SpainPulmonary Medicine Department, Hospital Universitario y Politécnico La Fe, 46023 Valencia, SpainPulmonary Medicine Department, Hospital Universitario y Politécnico La Fe, 46023 Valencia, SpainPulmonary Medicine Department, Hospital Universitario y Politécnico La Fe, 46023 Valencia, SpainLaboratory Department, Hospital Universitario y Politécnico La Fe, 46023 Valencia, SpainCIBER Enfermedades Respiratorias (CIBERES), 28029 Madrid, SpainCIBER Enfermedades Respiratorias (CIBERES), 28029 Madrid, SpainCIBER Enfermedades Respiratorias (CIBERES), 28029 Madrid, SpainCIBER Enfermedades Respiratorias (CIBERES), 28029 Madrid, SpainBronchiectasis is a chronic structural disease associated with exacerbations that provoke systemic inflammation. We aimed to evaluate the systemic acute proinflammatory cytokine and its biomarker profiles during and after exacerbations and its relationship with the severity of episode, microbiological findings, and the bronchiectasis severity index. This prospective observational study compared exacerbation and stable groups. Cytokine (interleukins (IL)-17a, IL-1β, IL-6, IL 8; tumor necrosis factor-alpha (α)) and high-sensitivity C-reactive protein (hsCRP) levels were determined by multiplex analysis on days 1, 5, 30, and 60 in the exacerbation group and on day 1 in the stable group. We recruited 165 patients with exacerbations, of which 93 were severe (hospitalized). Proinflammatory systemic IL-17a, IL-1β, IL-8, and tumor necrosis factor-α levels increased similarly on days 1 and 5 in severe and non-severe episodes, but on day 30, IL-17a, IL-8, and IL-6 levels were only increased for severe exacerbations. The highest IL-17a level occurred in patients with chronic plus the acute isolation of <i>Pseudomonas aeruginosa</i>. At 30 days, severe exacerbations were independently associated with higher levels of IL-17 (Odds ratio (OR) 4.58), IL-6 (OR 4.89), IL-8 (OR 3.08), and hsCRP (OR 6.7), adjusted for age, the bronchiectasis severity index, and treatment duration. Exacerbations in patients with chronic <i>P. aeruginosa</i> infection were associated with an increase in IL-17 and IL-6 at 30 days (ORs 7.47 and 3.44, respectively). Severe exacerbations elicit a higher systemic proinflammatory response that is sustained to day 30. Patients with chronic <i>P. aeruginosa</i> infection had impaired IL-17a reduction. IL-17a could be a useful target for measuring systemic inflammation.https://www.mdpi.com/2077-0383/9/8/2631bronchiectasisinflammationexacerbation |
| spellingShingle | Rosario Menéndez Raúl Méndez Isabel Amara-Elori Soledad Reyes Beatriz Montull Laura Feced Ricardo Alonso Rosanel Amaro Victoria Alcaraz Laia Fernandez-Barat Antoni Torres Systemic Inflammation during and after Bronchiectasis Exacerbations: Impact of <i>Pseudomonas aeruginosa</i> Journal of Clinical Medicine bronchiectasis inflammation exacerbation |
| title | Systemic Inflammation during and after Bronchiectasis Exacerbations: Impact of <i>Pseudomonas aeruginosa</i> |
| title_full | Systemic Inflammation during and after Bronchiectasis Exacerbations: Impact of <i>Pseudomonas aeruginosa</i> |
| title_fullStr | Systemic Inflammation during and after Bronchiectasis Exacerbations: Impact of <i>Pseudomonas aeruginosa</i> |
| title_full_unstemmed | Systemic Inflammation during and after Bronchiectasis Exacerbations: Impact of <i>Pseudomonas aeruginosa</i> |
| title_short | Systemic Inflammation during and after Bronchiectasis Exacerbations: Impact of <i>Pseudomonas aeruginosa</i> |
| title_sort | systemic inflammation during and after bronchiectasis exacerbations impact of i pseudomonas aeruginosa i |
| topic | bronchiectasis inflammation exacerbation |
| url | https://www.mdpi.com/2077-0383/9/8/2631 |
| work_keys_str_mv | AT rosariomenendez systemicinflammationduringandafterbronchiectasisexacerbationsimpactofipseudomonasaeruginosai AT raulmendez systemicinflammationduringandafterbronchiectasisexacerbationsimpactofipseudomonasaeruginosai AT isabelamaraelori systemicinflammationduringandafterbronchiectasisexacerbationsimpactofipseudomonasaeruginosai AT soledadreyes systemicinflammationduringandafterbronchiectasisexacerbationsimpactofipseudomonasaeruginosai AT beatrizmontull systemicinflammationduringandafterbronchiectasisexacerbationsimpactofipseudomonasaeruginosai AT laurafeced systemicinflammationduringandafterbronchiectasisexacerbationsimpactofipseudomonasaeruginosai AT ricardoalonso systemicinflammationduringandafterbronchiectasisexacerbationsimpactofipseudomonasaeruginosai AT rosanelamaro systemicinflammationduringandafterbronchiectasisexacerbationsimpactofipseudomonasaeruginosai AT victoriaalcaraz systemicinflammationduringandafterbronchiectasisexacerbationsimpactofipseudomonasaeruginosai AT laiafernandezbarat systemicinflammationduringandafterbronchiectasisexacerbationsimpactofipseudomonasaeruginosai AT antonitorres systemicinflammationduringandafterbronchiectasisexacerbationsimpactofipseudomonasaeruginosai |